Experimental Alzheimer’s drug significantly slowed patients’ cognitive decline, buoying hopes for treatment

(By Damian Garde for STAT)

CHICAGO — An investigational Alzheimer’s drug significantly slowed patients’ cognitive decline in a large clinical trial, unexpected and unprecedented results that could move the treatment’s makers to roll the dice on an early approval. Continue reading article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.